Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program

A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047

(2009) Wen-Lin Kuo et al.   BMC Medicine

The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer

(2009) K. Dredge et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting Ornithine Decarboxylase Impairs Development of MYCN-Amplified Neuroblastoma

(2009) R. J. Rounbehler et al.   CANCER RESEARCH

Disrupting Polyamine Homeostasis as a Therapeutic Strategy for Neuroblastoma

(2009) N. F. Evageliou et al.   CLINICAL CANCER RESEARCH

In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells

(2008) Amy Hacker et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial

(2008) Frank L. Meyskens et al.   Cancer Prevention Research

ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

(2008) M. D. Hogarty et al.   CANCER RESEARCH

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

(2007) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER